Our journey continues to evolve thanks to our diverse team of experts sharing mutual commitment and dedication, to addressing the immense clinical unmet need for mitochondrial diseases
We strive to be the global leader in developing novel Mitochondrial Cell Therapies to treat people stricken with mitochondrial diseases.
Every day, together with the world’s leading scientists, clinicians and patients’ groups we are translating our mitochondrial science into meaningful therapies for mitochondrial diseases – anywhere from ultra-rare to more common ones.
Making our therapy available to patients around the world as fast as responsible:
Sheba Medical Center
Tel Aviv, Israel
United States (coming soon)
Kendall Square, Cambridge
Our ability to execute is driven by our highly experienced executive team, comprehensive regulatory strategy and clinical development plan in partnerships with key physicians and advisors.
Co-founder & CEO
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.
Noa is highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.
Chief Medical Officer
Dr. Alan Jacobs brings over 20 years of experience leading international teams in the research and development of therapeutics and medical devices. His executive experience in companies such as Elan Pharmaceuticals, PerceptiMed and Hemostemix also encompasses clinical development, regulatory affairs, manufacturing, fundraising, grant funding, and Intellectual Property. He has been awarded numerous research grants, fellowships, patents, awards and honors, and has authored many publications. He has served on several committees, including the National Institutes of Health NINDS Stroke Progress Review Group, American Society of Experimental Neurotherapeutics, Health Technology Center Expert Panel Stem Cell Technology, and the American Society of Neurotransplantation and Repair.
VP, Corporate Development and Head of EU Operations
Shay is a highly experienced leader in commercialization of rare disease and biosimilar products. Former Regional Director at Biogen, Shay led commercial operation across multiple countries in EU and non-EU countries. Shay holds an MSc. from The Weizmann Institute of Science and an MBA from INSEAD.
Amnon is a seasoned quality executive, experienced in the complete life cycle of drug development, covering biotech, pharmaceutical and cell therapy products, from the R&D stage through nonclinical and toxicological safety studies, clinical trials, process and method development, GMP manufacturing, facility validation, support of regulatory submissions for US/EU/MHRA clinical trials and product approvals, to global distribution of commercial drug products. Amnon has established effective and compliant GXP Quality Systems in the US, Switzerland, EU, and the UK, and managed GXP compliance programs for global clinical trials, for US and International Health Authority inspections (FDA, EMA, MHRA), including for-cause inspections. Amnon is recognized as a thought-leader on the Phase-Appropriate application of GMP to drug development, and on the application of Science and Compliance-based Quality oversight. Amnon has been a volunteer at the ISPE and PDA professional organizations, collaborating with FDA and international regulators on various programs and technical reports.
Chairman of the Board
John joined Minovia Therapeutics in February 2019 and brings over 25 years of experience in biopharmaceuticals. Mr. Cox is currently the Chief Executive Officer of Repertoire Immune Medicines, and was formerly the CEO of Bioverativ, which he built and grew from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B. In February 2018 Mr. Cox led Bioverativ to a successful acquisition by Sanofi for $11.6B.
Co-founder, CEO & Board member
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with passion to help children ans adults with mitochondrial diseases worldwide.
Co-founder & Board Member
Uri is a serial entrepreneur and inventor. He is the former General Manager of Soreq Nuclear Center, Israel. Uri successfully co-founded 6 hi-tech companies: Opal, X-Technologies, Kailight, Radiancy, Sonotron and Oplon.
Co-founder & Board Member
Efraim is an Ex-Deputy Head, Israel Institute for Biological Research. He is a former executive at Siemens Israel and a serial angel investor in Israeli start-up companies.
Zeev is an Angel investor and member of the board of several companies. Zeev is the former Chief Executive Officer and Partner at I.B.I. Investment Banking and brings years of vast experience in brokerage and investment banking.